NCT02496884View on ClinicalTrials.gov

Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 26, 2015

Primary Completion Date

July 6, 2017

Study Completion Date

July 6, 2017

Conditions
Fibromyalgia
Interventions
DRUG

DS-5565

DS-5565 7.5 mg tablet for oral use

DRUG

Placebo

Placebo tablet for oral use to match DS-5565 7.5 mg tablet

Trial Locations (39)

19610

Wyomissing

25304

Charleston

26505

Morgantown

27262

High Point

29651

Greer

32713

DeBary

33013

Hialeah

33144

Miami

34601

Brooksville

34744

Kissimmee

37919

Knoxville

45224

Cincinnati

48439

Grand Blanc

57702

Rapid City

75093

Plano

77098

Houston

80918

Colorado Springs

85018

Phoenix

90033

Los Angeles

92324

Colton

92705

Santa Ana

98007

Bellevue

Unknown

Plovdiv

Sevlievo

Sofia

Stara Zagora

Varna

Prague

Říčany

Budapest

Nyíregyháza

Elblag

Krakow

Cluj-Napoca

Johannesburg

Pretoria

Barcelona

Santiago de Compostela

Valencia

Sponsors

Lead Sponsor

Daiichi Sankyo

Collaborators (1)

Syneos Health
All Listed Sponsors
collaborator

Syneos Health

OTHER

lead

Daiichi Sankyo

INDUSTRY